Organoid technology and applications in cancer research
TL;DR: In conclusion, organoids represent an excellent preclinical model for human tumors, promoting the translation from basic cancer research to clinical practice and its applications in cancer research are summarized.
read more
Abstract: During the past decade, the three-dimensional organoid technology has sprung up and become more and more popular among researchers. Organoids are the miniatures of in vivo tissues and organs, and faithfully recapitulate the architectures and distinctive functions of a specific organ. These amazing three-dimensional constructs represent a promising, near-physiological model for human cancers, and tremendously support diverse potential applications in cancer research. Up to now, highly efficient establishment of organoids can be achieved from both normal and malignant tissues of patients. Using this bioengineered platform, the links of infection-cancer progression and mutation-carcinogenesis are feasible to be modeled. Another potential application is that organoid technology facilitates drug testing and guides personalized therapy. Although organoids still fail to model immune system accurately, co-cultures of organoids and lymphocytes have been reported in several studies, bringing hope for further application of this technology in immunotherapy. In addition, the potential value in regeneration medicine might be another paramount branch of organoid technology, which might refine current transplantation therapy through the replacement of irreversibly progressively diseased organs with isogenic healthy organoids. In conclusion, organoids represent an excellent preclinical model for human tumors, promoting the translation from basic cancer research to clinical practice. In this review, we outline organoid technology and summarize its applications in cancer research.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Targeting mTOR for cancer therapy
TL;DR: Recent advances in exploring mTOR signaling and the development of mTOR inhibitors for cancer therapy are updated and the mechanisms underlying the resistance to mTOR inhibitor in cancer cells are discussed.
Current Perspectives on Nasopharyngeal Carcinoma.
TL;DR: To improve outcome of NPC patients, novel cellular and in vivo systems are needed to allow an understanding of the underling molecular events causal for NPC pathogenesis and for identifying novel therapeutic targets and effective therapies.
215
Modeling neoplastic disease with spheroids and organoids
TL;DR: Recent advances in the use of spheroids and organoids for cancer modeling are summarized, focusing on their innovative translational applications, looking at future challenges, and comparing them with most widely used animal models.
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.
TL;DR: Common organoid lines are described, the potential clinical applications, and the current limitations are outlined, to bring basic research closer to clinical practice.
Metastatic disease in head & neck oncology
Pisani P,Mario Airoldi,Anastasia Allais,Paolo Aluffi Valletti,Mariapina Battista,Marco Benazzo,Roberto Briatore,Salvatore Cacciola,Salvatore Cocuzza,Andrea Colombo,Bice Conti,Alberto Costanzo,Laura Della Vecchia,Nerina Denaro,Cesare Fantozzi,Danilo Galizia,Massimiliano Garzaro,Ida Genta,Gabriela Alejandra Iasi,Marco Krengli,Vincenzo Landolfo,Giovanni Vittorio Lanza,Mauro Magnano,Maurizio Mancuso,Roberto Maroldi,Laura Masini,Marco Merlano,Marco Piemonte,Silvia Pisani,Adriele Prina-Mello,Luca Prioglio,Maria Gabriella Rugiu,F. Scasso,Agostino Serra,Guido Valente,Micol Zannetti,Angelo Zigliani +36 more
TL;DR: The aim of the present review is to provide an update on distant metastasis in head and neck oncology, with particular attention reserved to tumours with distant metastases and positive for EBV and HPV, and the oligometastatic concept.
References
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf,Florin-Andrei Taran,Markus Wallwiener,Christina B. Walter,Bernhard K. Krämer,Eva-Maria Grischke,Sara Y. Brucker +6 more
TL;DR: This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
7.4K
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
Toshiro Sato,Robert G.J. Vries,Hugo J. Snippert,Marc van de Wetering,Nick Barker,Daniel E. Stange,Johan H. van Es,Arie Abo,Pekka Kujala,Peter J. Peters,Hans Clevers +10 more
TL;DR: It is concluded that intestinal cryptvillus units are self-organizing structures, which can be built from a single stem cell in the absence of a non-epithelial cellular niche.
6.4K
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Toshiro Sato,Daniel E. Stange,Marc Ferrante,Marc Ferrante,Robert G.J. Vries,Johan H. van Es,Stieneke van den Brink,Winan J. van Houdt,Apollo Pronk,Joost van Gorp,Peter D. Siersema,Hans Clevers +11 more
TL;DR: A technology that can be used to study infected, inflammatory, or neoplastic tissues from the human gastrointestinal tract is developed that might have applications in regenerative biology through ex vivo expansion of the intestinal epithelia.
3.4K
Related Papers (5)
Marc van de Wetering,Hayley E. Francies,Joshua M. Francis,Joshua M. Francis,Gergana Bounova,Francesco Iorio,Apollo Pronk,Winan J. van Houdt,Joost van Gorp,Amaro Taylor-Weiner,Lennart Kester,Anne McLaren-Douglas,Joyce Blokker,Sridevi Jaksani,Sina Bartfeld,Richard Volckman,Peter van Sluis,Vivian S. W. Li,Sara Seepo,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Kristian Cibulskis,Scott L. Carter,Scott L. Carter,Aaron McKenna,Michael S. Lawrence,Lee Lichtenstein,Chip Stewart,Jan Koster,Rogier Versteeg,Alexander van Oudenaarden,Julio Saez-Rodriguez,Robert G.J. Vries,Gad Getz,Gad Getz,Lodewyk F. A. Wessels,Michael R. Stratton,Ultan McDermott,Matthew Meyerson,Matthew Meyerson,Mathew J. Garnett,Hans Clevers +41 more
Jarno Drost,Hans Clevers +1 more
Norman Sachs,Joep de Ligt,Oded Kopper,Ewa Gogola,Gergana Bounova,Fleur Weeber,Anjali Vanita Balgobind,Karin Wind,Ana Gracanin,Harry Begthel,Jeroen Korving,Ruben van Boxtel,Alexandra A. Duarte,Daphne Lelieveld,Arne Van Hoeck,Robert F Ernst,Francis Blokzijl,Isaac J. Nijman,Marlous Hoogstraat,Marieke van der Ven,David A. Egan,Vittoria Zinzalla,Jürgen Moll,Sylvia F. Boj,Emile E. Voest,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Paul J. van Diest,Sven Rottenberg,Sven Rottenberg,Robert G.J. Vries,Edwin Cuppen,Hans Clevers +32 more
Georgios Vlachogiannis,Somaieh Hedayat,Alexandra Vatsiou,Yann Jamin,Javier Fernández-Mateos,Khurum Khan,Khurum Khan,Andrea Lampis,Katherine Eason,Ian Said Huntingford,Rosemary Burke,Mihaela Rata,Dow-Mu Koh,Dow-Mu Koh,Nina Tunariu,Nina Tunariu,David J. Collins,Sanna Hulkki-Wilson,Chanthirika Ragulan,Inmaculada Spiteri,Sing Yu Moorcraft,Ian Chau,Sheela Rao,David Watkins,Nicos Fotiadis,Maria Antonietta Bali,Maria Antonietta Bali,Mahnaz Darvish-Damavandi,Hazel Lote,Hazel Lote,Zakaria Eltahir,Elizabeth C Smyth,Ruwaida Begum,Paul A. Clarke,Jens C. Hahne,Mitchell Dowsett,Johann S. de Bono,Paul Workman,Anguraj Sadanandam,Matteo Fassan,Owen J. Sansom,Suzanne A. Eccles,Naureen Starling,Chiara Braconi,Chiara Braconi,Andrea Sottoriva,Simon P. Robinson,David Cunningham,Nicola Valeri,Nicola Valeri +49 more